Critical Path Institute Appoints Dr. Aoife Brennan to Board of Directors

TUCSON, Ariz., July 16, 2025 — Critical Path Institute® (C-Path) today announced the appointment of Aoife Brennan, M.D., to its Board of Directors. Dr. Brennan brings extensive experience in biopharmaceutical leadership, clinical development, and regulatory strategy to C-Path's growing efforts to advance global drug development and data-driven science.

Dr. Aoife Brennan

Dr. Brennan is president and CEO of Climb Bio, a clinical-stage biotech company focused on treatments for immune-mediated diseases. She led the company through the acquisition and relaunch of Tenet Medicines under the Climb Bio name. Previously, she served as CEO and chief medical officer at Synlogic, where she oversaw development programs in rare metabolic diseases. At Biogen, she led efforts resulting in the global approval of ALPROLIX, ELOCTATE, and SPINRAZA.

Dr. Brennan also serves on the boards of Cerevance, and Xilio Therapeutics. She earned her medical degree from Trinity College Dublin and completed postgraduate training in internal medicine, endocrinology, and metabolism. She is also a graduate of the Harvard Medical School Scholars in Clinical Science Program.

"Dr. Brennan has spent her career driving progress in science and medicine to improve lives," said Wainwright Fishburn, J.D., Chairman of the Board at C-Path. "She is an exceptional leader whose insight and experience will help guide C-Path's work to make drug development more collaborative, more transparent, and more reliable for the people who depend on it."

"At a time when collaboration across sectors is essential, Dr. Brennan's expertise across clinical science and global biotech leadership will ensure we are focused on solving the right problems," said Klaus Romero, M.D., M.S., FCP, CEO of C-Path. "Her perspective will be invaluable as we continue our mission to accelerate the development of safe and effective medical products."

The appointment is effective immediately.

About Critical Path Institute

Founded in 2005, as a public-private partnership in response to the FDA's Critical Path Initiative, Critical Path Institute® (C-Path) celebrates its 20th anniversary as a vital, independent, nonprofit. C-Path's mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path's global headquarters is located in Tucson, Arizona and C-Path's Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.

Media Contacts:

Roxan Triolo Olivas
C-Path
520.954.1634
rolivas@c-path.org

Kissy Black
C-Path
615.310.1894
kblack@c-path.org